589 related articles for article (PubMed ID: 30080934)
1. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
2. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
Jayadevappa R; Chhatre S; Malkowicz SB; Parikh RB; Guzzo T; Wein AJ
JAMA Netw Open; 2019 Jul; 2(7):e196562. PubMed ID: 31268539
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
4. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
[TBL] [Abstract][Full Text] [Related]
5. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
7. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
Hershman DL; Unger JM; Wright JD; Ramsey S; Till C; Tangen CM; Barlow WE; Blanke C; Thompson IM; Hussain M
JAMA Oncol; 2016 Apr; 2(4):453-61. PubMed ID: 26720308
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
9. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
10. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation.
Wallis CJ; Mahar AL; Satkunasivam R; Herschorn S; Kodama RT; Lee Y; Kulkarni GS; Narod SA; Nam RK
Urology; 2016 Nov; 97():145-152. PubMed ID: 27502032
[TBL] [Abstract][Full Text] [Related]
12. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
Baik SH; Kury FSP; McDonald CJ
J Clin Oncol; 2017 Oct; 35(30):3401-3409. PubMed ID: 28841388
[TBL] [Abstract][Full Text] [Related]
13. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.
Yang DD; Krasnova A; Nead KT; Choueiri TK; Hu JC; Hoffman KE; Yu JB; Spratt DE; Feng FY; Trinh QD; Nguyen PL
Ann Oncol; 2018 Feb; 29(2):386-391. PubMed ID: 29267861
[TBL] [Abstract][Full Text] [Related]
16. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
Eur Urol; 2013 Jul; 64(1):159-66. PubMed ID: 22537796
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer's Perspective.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Manag Care Spec Pharm; 2019 Feb; 25(2):225-234. PubMed ID: 30698095
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
19. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
[TBL] [Abstract][Full Text] [Related]
20. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.
Kao LT; Lin HC; Chung SD; Huang CY
Asian J Androl; 2017; 19(4):414-417. PubMed ID: 27232853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]